Houte Hans Van Sells 3,499 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,499 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the completion of the sale, the chief financial officer now owns 68,333 shares in the company, valued at $876,712.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.04, for a total value of $16,699.48.
• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $68,256.24.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $12.78 on Friday. The business has a 50 day simple moving average of $13.80 and a two-hundred day simple moving average of $9.88. Nurix Therapeutics, Inc. has a 1 year low of $4.22 and a 1 year high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The company had revenue of $16.59 million during the quarter, compared to analysts’ expectations of $14.58 million. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its position in Nurix Therapeutics by 14.8% in the 3rd quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock valued at $122,000 after buying an additional 2,002 shares during the period. Raymond James & Associates boosted its holdings in shares of Nurix Therapeutics by 3.1% in the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock valued at $1,042,000 after purchasing an additional 3,018 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Nurix Therapeutics by 67.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares during the period. Exchange Traded Concepts LLC increased its holdings in Nurix Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 15,823 shares of the company’s stock worth $163,000 after purchasing an additional 4,012 shares during the period. Finally, Wellington Management Group LLP raised its position in Nurix Therapeutics by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 145,053 shares of the company’s stock valued at $1,140,000 after purchasing an additional 4,163 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have commented on NRIX. HC Wainwright lowered their price objective on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Robert W. Baird increased their price target on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Morgan Stanley raised their price objective on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Finally, Royal Bank of Canada boosted their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $21.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.